Literature DB >> 3509953

Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat.

P E Goss, M Jarman, J R Wilkinson, R C Coombes.   

Abstract

4-Hydroxyandrost-4-ene-3,17-dione (HAD) is a potent and selective inhibitor of the enzyme complex aromatase, both in vitro and in vivo. The glucuronide is a major metabolite in the urine of patients and in the bile of rats given HAD and it was identified by chemical ionization-MS of the permethylated derivative. HAD glucuronide was quantified by first converting it enzymically into HAD, then determining HAD by capillary column GC-MS of the perfluorotolyl derivative using 4-hydroxyandrost-2,4-diene-3,17-dione as internal standard.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3509953     DOI: 10.1016/0022-4731(86)90128-7

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  8 in total

Review 1.  Clinical pharmacokinetics of aromatase inhibitors and inactivators.

Authors:  Per Lønning
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 3.  Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.

Authors:  L R Wiseman; K L Goa
Journal:  Drugs Aging       Date:  1996-10       Impact factor: 3.923

4.  Serum kinetics of the anti-cancer agent 4-hydroxyandrostenedione in the rat.

Authors:  J Khubieh; G W Aherne; J Chakraborty
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men.

Authors:  M Dowsett; P Lloyd
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 6.  Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.

Authors:  L R Wiseman; D McTavish
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

7.  Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione.

Authors:  R C Stein; M Dowsett; A Hedley; J Davenport; J C Gazet; H T Ford; R C Coombes
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 8.  Aromatase inhibitors in malignant diseases of aging.

Authors:  D C Johannessen; P E Lønning
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.